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Ulcers, crater-like sores, formed in the stomach and duodenum are called gastric and
duodenal ulcers, respectively. Stomach and duodenum ulcer are generally referred to as
peptic ulcers. Helicobacter pylori infection is the major cause of peptic ulcer, since 85 to 95 %
of patients with peptic ulcer have this organism (1). Non-steroidal anti-inflammatory
drugs such as aspirin can also cause or worsen ulcer (2). Pantoprazole, a proton pump
inhibitor, which belongs to the benzimidazole groups, is used for the treatment of peptic
ulcer. Pantoprazole inhibits gastric acid by blocking the H+/K+-adenosine triphospha-
tase enzyme system (the proton pump) of gastric parietal cells (3). Pantoprazole under-
goes degradation at a low pH of the esophagus and stomach; it is therefore given as en-
teric-coated tablets. The enteric coating dissolves only at alkaline pH, thus preventing
drug degradation in acidic environment of the stomach (4). The therapeutic concen-
tration of a drug in blood can be maintained for a prolonged period of time by admini-
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stering it in the form of a sustained release dosage form. Amongst sustained release formu-
lations, sustained release tablet dosage forms have become extremely popular in modern
therapeutics. Drugs with short half-lives are ideal candidates for sustained drug delivery
(5). Many drugs have been marketed as sustained release tablets owing to their cost effec-
tiveness and greater patient compliance. In the present study, we made an attempt to de-
liver pantoprazole in a sustained manner using delayed release tablets and studied their ef-
fectiveness for treating ulcer in a water immersion stress induced animal model.
EXPERIMENTAL
Materials
Pantoprazole was a gift from Alembic Pharma, Baroda, India. The polymers, hydro-
xypropylmethylcellulose (HPMC) and polyvinyl pyrrolidone (PVP) were purchased from
SD Fine Chem. Ltd., India. Cassava starch was obtained from Central Tuber Crops Re-
search Institute, India. Cellulose acetate phthalate (CAP), drug coat L100 (methacrylic
acid copolymer), Eudragit L100 and microcrystalline cellulose (Avicel PH 102) were ob-
tained as a gift from Strides Arco Lab., India. All other chemicals used for the study
were of analytical grade.
Preparation of sustained release tablets
Pantoprazole tablets were prepared by the wet granulation method (6). Specified
quantity of pantoprazole, hydroxypropylmethylcellulose, cassava starch and polyvinyl
pyrrolidone and Avicel PH 102 were weighed according to the formula given in Table I
and transferred into a mortar with pestle and mixed thoroughly. The powder mass was
mixed with a 5 % starch paste to obtain a sluggy mass, which was passed through a sieve
with aperture pore of 1.4 mm to obtain granules. The granules prepared were dried at 40
°C for 4 h. The dried granules were screened through sieves of 0.71 mm and 0.355 mm and
stored for further studies. Required quantities of magnesium stearate and talc were finally
added and mixed thoroughly. The mixture was directly punched into tablets weighing
about 200 mg (containing 40 mg of pantoprazole), using a rotary tablet compression
machine (12 stations, Karnavati, India), and 8-mm diameter concave punches. The diffe-
rent batches of pantoprazole tablets were collected and stored in airtight containers.
Evaluation of granules
Size analysis by optical microscopy. – Dry granules were uniformly spread on a glass
slide. Granule particle size was measured along the longest and the shortest axes (cross
shaped measurement) using an optical microscope (Olympus CH20i, India) after
calibration. Average of these two readings is given as the mean diameter of particles.
The diameter of at least 50 granules in each batch was determined.
Bulk density, tapped density and Carr’s index. – Bulk density is the ratio of the total
mass of powder to the bulk volume of powder. It was measured by pouring weighed
powder into a graduated measuring cylinder and the volume was noted. Tapped den-
sity is the ratio of the total mass of powder to the tapped volume of powder. Tapped
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volume was measured by tapping the powder to constant volume. Carr’s index indicates
the powder flow properties. It is expressed in percentage and is given by (Dt–Db/Dt) × 100,
where Dt is tapped density and Db is bulk density (7).
Angle of repose. – Angle of repose is the maximum angle possible between the sur-
face of a pile of powder and the horizontal plane. Sufficient quantity of pantoprazole
granules was passed through a funnel from a particular height (2 cm) onto a flat surface
until it formed a heap, which touched the tip of the funnel. The height and radius of the
heap were measured. The angle of repose (q) was calculated using the formula; q = tan–1
(h/r); where, h is the height of the pile in cm and r is the radius of the pile in cm (7).
Evaluation of sustained release tablets
Hardness, friability and mass variation. – The tablets were subjected to a hardness test.
It was carried out by using a hardness tester (SECOR, India) and expressed in kg cm–2.
For friability (%), from each batch, twenty tablets were selected randomly and friability
was determined using the Cintex friability test apparatus, India. 20 tablets were ran-
domly selected for mass variation study from each lot and weighed individually, and
the average mass was determined. The percent deviation of each tablet’s mass from the
average mass was calculated according to the official method (8).
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F1 40 – – – 154 q.s. 2 4
F2 40 20 – – 134 q.s. 2 4
F3 40 40 – – 114 q.s. 2 4
F4 40 60 – – 94 q.s. 2 4
F5 40 80 – – 74 q.s. 2 4
F6 40 100 – – 54 q.s. 2 4
F7 40 – 20 – 134 q.s. 2 4
F8 40 – 40 – 114 q.s. 2 4
F9 40 – 60 – 94 q.s. 2 4
F10 40 – 80 – 74 q.s. 2 4
F11 40 – 100 – 54 q.s. 2 4
F12 40 – – 20 134 q.s. 2 4
F13 40 – – 40 114 q.s. 2 4
F14 40 – – 60 94 q.s. 2 4
F15 40 – – 80 74 q.s. 2 4
F16 40 – – 100 54 q.s. 2 4
a Total mass of each tablet: 200 mg.
q.s. – quantum satis
Drug content uniformity. – The drug was extracted completely from the tablets in pH 6.8
phosphate buffer and the solution was filtered. Filtrate (1 mL) was diluted with pH 6.8
phosphate buffer. Absorbance of the resulting solution was measured with a UV-Visible
spectrophotometer UV-1700 (Shimadzu, Japan) at 289 nm.
Enteric coating of compressed tablets
Preparation of enteric coating solution. – The coating solution was composed of Eudra-
git L100 or cellulose acetate phthalate or drug coat L100 as an enteric polymer, titanium
dioxide as opacifier, diethyl phthalate as plasticizer, and acetone/isopropyl alcohol mix-
ture (1:2) as solvent (Table II). Titanium dioxide was triturated in a glass mortar with a
small amount of solvent mixture and filtered through muslin cloth into the polymer so-
lution already prepared with one half of the solvent mixture. Diethyl phthalate was ad-
ded and the volume made up with the rest of the solvent mixture. Finally, this mixture
was constantly stirred for 1 h using a mechanical stirrer at 1000 rpm and the stirred coat-
ing solution was again filtered through muslin cloth.
Enteric coating of pantoprazole compressed tablets by the dipping method. – For enteric
coating, batches F3, F9 and F15 were selected based on their physicochemical charac-
teristics and release profile, and hereafter they are referred to as ECF3, ECF9 and ECF15,
respectively. The compressed tablets were coated with the enteric coating solution (com-
position is given above) by the dipping method. Coating was continued till the required
mass gain was achieved. The coated tablets were studied for their mass variation, thick-
ness, uniformity of drug content and in vitro dissolution. Enteric coating films were also
prepared by pouring an aliquot amount of solution onto Petri plates and dried at room
temperature.
Physicochemical evaluation of coating films. – The dried enteric coating polymer films
were cut into 1-cm2 pieces and evaluated for their thickness, mass and solubility. The
thickness of dried films was determined by a Vernier caliber. Film solubility was studied
at pH 1.2 and 6.8. The 1×1 cm coating film was selected, weighed and transferred into a
beaker containing 20 mL of specified pH medium, which was stirred for 1 h at 37 ± 1 °C
and finally film solubility was measured.
In vitro drug release. – A USP dissolution apparatus type II/10 (USP XXIII) was em-
ployed to study the in vitro drug release from various batches. The dissolution medium
used was 900 mL of acidic buffer of pH 1.2 for 2 h and phosphate buffer of pH 6.8 for 10 h.
The temperature was maintained at 37 ± 0.5 °C and the stirring rate was 100 rpm.
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Table II. Coating solution composition
Ingredient Content (%, m/m)





Samples (2 mL) were withdrawn at regular time intervals and the same volume was re-
placed with fresh dissolution medium. The samples were measured for drug content at
284 nm (pH 1.2) and at 289 nm (pH 6.8) against blank.
Release kinetics. – The in vitro release data of selected formulations (ECF3, ECF9 and
ECF15 coated with cellulose acetate phthallate) were fitted to various kinetic equations
such as zero order, first-order, Higuchi and Korsmeyer-Peppas (11). For zero-order (Q =
Q0 – k0t), the graph was plotted for cumulative percent of drug released vs. time, first
order release (ln Q = ln Q0 – k1 t) graph was plotted in log cumulative percent of drug
remaining vs. time; In the case of Higuchi (Q = kH t1/2), the graph was plotted as cumu-
lative percent of drug released vs. square root of time, and for Korsmeyer-Peppas (Q/Q0
= k tn) the graph was plotted as log cumulative percent of drug released vs. log time. k0,
k1 and k2 are release rate constants, Q/Q0 is the fraction of drug released at time t, and n
is the diffusional release exponent, which is used to find out the drug release mecha-
nism. If the value of n is equal up to 0.5, the drug is released with a Fickian diffusion
mechanism, if n is in between 0.5 to 1.0, it indicates a non-Fickian or anomalous drug
release, whereas, n is 1.0 for zero-order release (11)
Stability studies. – For stability studies, the ECF3 tablets were stored at room tem-
perature and 40 °C (RH 75 %) over a period of 1 month (7). Samples were evaluated after
10, 20 and 30 days for different parameters such as physical appearance, hardness, mass
variation, drug content and dissolution.
In vivo studies
Animals. – Albino rats of Wistar strain of either sex weighing between 150–200 g were
obtained from the animal house of the Dayananda Sagar College of Pharmacy, Banga-
lore, India, after getting approval by the Dayananda Sagar College of Pharmacy’s Ani-
mal Ethics Committee of the same institution. The studies were performed in accordance
with the CPCSEA guidelines. The animal house was well ventilated and the animals were
maintained at a 12:12 h light/dark cycle in large spacious cages throughout the expe-
rimental period. They were given free access to food and water. All efforts were made to
minimize animal suffering.
Evaluation of antiulcer activity. – The antiulcer activity of the pantoprazole tablets en-
teric coated with CAP (ECF3) was evaluated using a water immersion stress induced
ulcer model (12). This is a simple method and the lesions produced by this model are
located in the glandular region of the stomach. The animals were divided into three
groups of six animals each. Group I was vehicle control, group II was stress control and
group III was treatment control and received the pantoprazole coated tablet formulation
(ECF3) at a dose level of 10 mg kg–1 body mass for 7 days prior to subjecting them to
stress. The animals were deprived of food for 24 h before experimentation, but had free
access to drinking water. After the treatment, the animals were made to swim in water at
25 ± 1 °C for 5 h. After 5 h of swimming, the animals were anaesthetized and the sto-
mach of each animal was opened and examined with a hand lens for the extent of ulce-
ration. The ulcerogenic indices were determined using the following scoring system:
shedding of epithelium = 10, petichial and frank haemorrhages = 20, one or two ulcers = 30,
many ulcers = 40 and perforated ulcers = 50. The score of the treated group was com-
pared with the stress control group.
135
B. Wilson et al.: Sustained release enteric coated tablets of pantoprazole: Formulation, in vitro and in vivo evaluation, Acta Pharm. 63
(2013) 131–140.
RESULTS AND DISCUSSION
Preparation of pantoprazole tablets
Pantoprazole tablets were prepared by the wet granulation method. In this study,
tablets were prepared using HPMC, cassava starch and PVP as hydrophilic release re-
tarding polymers in different concentrations (Table I). During optimization of the gran-
ules, low moisture sluggy masses were found to have more fines and high friability and
the high moisture sluggy masses were sticky in the sieving process. Hence, optimum
moisture (paste 5 %) was used for preparing the granules. This method produced nar-
row shaped granular particles with very low fines. The obtained granules were smooth
and almost uniformly sized.
Characterization of pantoprazole tablets
Precompression and post compression parameters. – Pantoprazole granules were evaluat-
ed for their yield, granule particle size, angle of repose, bulk density, tapped density and
compressibility and the results are given in Table III. The yield of granules ranged be-
tween 86 and 98 %. This could be considered a satisfactory yield value and was due to
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F1 97.82 ± 1.85 0.498 ± 0.05 0.306 ± 0.03 0.326 ± 0.03 6.13 ± 0.12 25.79 ± 0.24
F2 94.85 ± 0.94 0.545 ± 0.12 0.312 ± 0.04 0.335 ± 0.02 6.86 ± 0.15 26.95 ± 0.15
F3 95.37 ± 1.61 0.527 ± 0.06 0.358 ± 0.05 0.385 ± 0.04 7.01 ± 0.13 26.33 ± 0.17
F4 94.12 ± 2.05 0.542 ± 0.05 0.357 ± 0.03 0.384 ± 0.05 7.03 ± 0.09 28.31 ± 0.26
F5 93.43 ± 0.89 0.533 ± 0.21 0.359 ± 0.04 0.394 ± 0.03 8.88 ± 0.24 27.20 ± 0.14
F6 91.68 ± 1.44 0.535 ± 0.06 0.384 ± 0.04 0.429 ± 0.05 10.48 ± 0.20 30.27 ± 0.34
F7 94.23 ± 1.79 0.512 ± 0.04 0.312 ± 0.03 0.334 ± 0.06 6.58 ± 0.14 29.52 ± 0.14
F8 95.89 ± 1.90 0.548 ± 0.11 0.286 ± 0.05 0.313 ± 0.04 8.62 ± 0.07 26.13 ± 0.26
F9 97.14 ± 1.79 0.536 ± 0.05 0.306 ± 0.03 0.334 ± 0.05 8.38 ± 0.17 26.78 ± 0.18
F10 94.42 ± 1.18 0.559 ± 0.12 0.294 ± 0.05 0.324 ± 0.03 9.25 ± 0.23 28.09 ± 0.21
F11 93.57 ± 0.94 0.538 ± 0.06 0.307 ± 0.02 0.340 ± 0.03 9.70 ± 0.18 28.74 ± 0.36
F12 94.60 ± 1.45 0.507 ± 0.04 0.384 ± 0.02 0.406 ± 0.06 5.41 ± 0.32 25.47 ± 0.12
F13 94.86 ± 2.34 0.537 ± 0.05 0.394 ± 0.06 0.416 ± 0.05 5.28 ± 0.16 28.47 ± 0.19
F14 96.13 ± 1.93 0.523 ± 0.04 0.416 ± 0.05 0.457 ± 0.04 8.97 ± 0.06 29.79 ± 0.25
F15 97.37 ± 2.05 0.567 ± 0.15 0.384 ± 0.04 0.410 ± 0.03 6.34 ± 0.14 26.32 ± 0.14
F16 86.13 ± 0.85 0.545 ± 0.13 0.418 ± 0.03 0.472 ± 0.05 11.44 ± 0.12 30.79 ± 0.23
a Mean ± SD, n = 3.
b Mean ± SD, n = 50.
polymer binding properties of granules. The particles were found to possess a narrow
size distribution range with particle size from 0.50 ± 0.1 to 0.58 ± 0.15 mm. Bulk density
of the granules ranged from 0.29 ± 0.05 to 0.42 ± 0.03 g mL–1, while tapped densities rang-
ed between 0.31 ± 0.04 to 0.47 ± 0.05 g mL–1. The low compressibility values (5.28 ± 0.16
to 11.44 ± 0.12 %) and angle of repose (25.47 ± 0.12 to 30.79 ± 0.26°) indicate good flow-
ability of the prepared granules, which in turn indicates homogenous filling of the die
cavity during tablet compression (7).
Post compression parameters such as hardness, mass variation, content uniformity, fri-
ability and in vitro drug release of pantoprazole tablets are given in Table IV. Tablets should
have sufficient hardness to withstand handling without breaking or crumbling. Hardness
plays a vital role for drug release in the case of sustained release tablets. Average hardness
was found in the range of 4.73 to 8.40 kg cm–2. Friability of the tablets ranged from 0.01 to
0.11 % which is less than 1 %. Drug content uniformity ranged from 94.6 to 99.4 %.
Physicochemical evaluation of coating films. – It was found that the enteric coating
films of cellulose acetate phthalate, Eudragit L100 and drug coat L100 were completely
insoluble at pH 1.2 and soluble at pH 6.8.
In vitro drug release from compressed tablets and coated tablets. – The in vitro release of
pantoprazole from uncoated and coated tablets was studied at pH 1.2 acidic buffer for 2 h
and in phosphate buffer pH 6.8 for 10 h. The varying concentration of HPMC (F1 to F6),
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Table IV. Physicochemical evaluation of pantoprazole tablets
Batch
Parameter
Hardness (kg cm–2)b Average mass (g)c Content uniformity (%)a
F1 8.40 ± 0.02 0.201 ± 0.020 98.85 ± 0.21
F2 5.80 ± 0.12 0.199 ± 0.120 97.71 ± 0.15
F3 6.20 ± 0.35 0.204 ± 0.009 98.85 ± 0.34
F4 4.90 ± 0.21 0.203 ± 0.024 97.42 ± 0.42
F5 4.93 ± 0.15 0.208 ± 0.031 96.85 ± 0.16
F6 4.73 ± 0.42 0.205 ± 0.015 97.14 ± 0.09
F7 5.66 ± 0.17 0.199 ± 0.019 98.55 ± 0.48
F8 8.20 ± 0.16 0.209 ± 0.008 99.42 ± 0.26
F9 5.60 ± 0.24 0.198 ± 0.007 96.85 ± 0.35
F10 5.73 ± 0.25 0.203 ± 0.014 96.28 ± 0.42
F11 5.12 ± 0.34 0.206 ± 0.016 95.78 ± 0.13
F12 8.06 ± 0.18 0.198 ± 0.027 94.57 ± 0.18
F13 7.66 ± 0.09 0.207 ± 0.034 95.42 ± 0.38
F14 5.56 ± 0.24 0.206 ± 0.016 95.71 ± 0.27
F15 5.83 ± 0.08 0.204 ± 0.006 95.71 ± 0.36
F16 6.21 ± 0.13 0.199 ± 0.018 96.01 ± 0.15
a Mean ± SD, n = 3.
b Mean ± SD, n = 6.
c Mean ± SD, n = 20.
cassava starch (F7 to F11) and PVP (F12 to F16) in tablet formulations showed a marked
difference in their drug release pattern (data not shown). HPMC showed better sustain-
ed release properties than a cassava starch and PVP as release retarding polymers. The
cumulative percentage release of pantoprazole from the tablets varied from 65.0 ± 0.2 %
to 98.7 ± 0.1 % after 12 h depending on the polymer and drug polymer ratio. F-1 did not
show any sustained release. This could be explained by the fact that F-1 was prepared by
omitting the release retarding polymer. For delayed release delivery systems, it was es-
sential that the drug release would be minimal until the dosage form reached the intes-
tine. To present drug release in the stomach, the tablets prepared were enteric coated
(ECF3, ECF9 and ECF15) using CAP, Eudragit L100 and drug coat L100. None of the CAP
coated tablets showed drug release during the first 2 h at acidic pH 1 and drug release at
pH 6.8 took place in a sustained manner for a period of 12 h. The dissolution profiles of
ECF3, ECF9, and ECF15 (Fig. 1) demonstrated a pH dependent release mechanism. The
cumulative percentage release of the drug from coated tablets ECF3, ECF9 and ECF15
varied from to 67.6 ± 0.4 % to 81.6 ± 0.2 %.
Release kinetics. – The in vitro release data obtained from CAP coated tablets ECF3,
Eudragit L100 coated tablets ECF9 and drug coat L100 coated tablets ECF15 were fitted
to various kinetic models such as zero-order, first-order, Higuchi and Korsmeyer-Peppas
models (11). The release of pantoprazole from the tablets was first-order diffusion con-
trolled, as indicated by highest R2 values (Table V). The R2 value of the Higuchi model is
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Table V. Release kinetics of formulations ECF3, ECF9 and ECF15 coated with CAP
Formulation Release kinetics (R2)
Zero-order First-order Higuchi Korsmeyer-Peppas
R n
ECF3 0.94 0.99 0.96 0.83 0.12
ECF9 0.93 0.99 0.96 0.83 0.13
ECF15 0.95 0.99 0.96 0.80 0.09
Fig. 1. In vitro release of pantoprazole from CAP coated tablet formulations ECF3, ECF9 and ECF15,
Mean ± SD, n = 3.
0.96 for all formulations. This indicates that the in vitro drug release data fit linearly to the
Higuchi model. The n value was 0.12, 0.13 and 0.09 for ECF3, ECF7 and ECF15, respec-
tively. The n value of the Korsmeyer-Peppas model was used to determine the mecha-
nism of drug release from the dosage forms. All the cases the n value was less than 0.5
indicating that the release mechanism was probably Fickian diffusion (11). The diffusion
mechanism is further supported by high R2 values in the Higuchi model (Table V).
Stability studies. – The stability study results of CAP tablets ECF3 are shown in Table
VI. There were no significant changes in their physical appearance, average mass, hard-
ness and drug content. The release profile did not show any significant changes either.
Hence, it can be concluded that the developed tablets were stable and retained their
pharmaceutical properties during a period of 1 month.
Animal studies. – The average ulcer score for the vehicle control group, stress control
group and treated group was 15 ± 2, 97 ± 3 and 35 ± 1, respectively. The cellulose acetate
phthalate coated tablet formulation ECF3 significantly reduced the incidence and seve-
rity of ulcer.
CONCLUSIONS
Designing a delayed release tablet with sustained release properties may avoid
drug release in the acidic environment of the stomach. This may minimize fluctuations
of drug level in blood, prolong therapeutic drug level in blood, improve drug efficacy
and patient compliance. The enteric coated, especially CAP drug coated tablets, did not
release the drug in the acidic pH 1.2 for a period of 2 h and released the in the intestinal
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Initial Room temperature 45 °C (RH 75 %)



















0.205 ± 0.027 0.255 ± 0.014 0.256 ± 0.035 0.260 ± 0.016 0.257 ± 0.018 0.259 ± 0.029 0.262 ± 0.035
Hardness
(kg cm–2)b
6.6 ± 0.4 6.5 ± 0.1 6.6 ± 0.2 6.6 ± 0.1 6.4 ± 0.1 6.4 ± 0.2 6.3 ± 0.1
Drug
content (%)a
100 ± 0.0 99.54 ± 0.1 99.51 ± 0.1 99.4 ± 0.1 99.8 ± 0.1 99.47 ± 0.1 99.56 ± 0.1
CDRa (%) 87.7 ± 0.1 87.31 ± 0.1 87.43 ± 0.2 87.1 ± 0.2 87.1 ± 0.4 86.78 ± 0.2 86.5 ± 0.5
RH – relative humidity
a Mean ± SD, n = 20.
b Mean ± SD, n = 6.
c Mean ± SD, n = 3.
CDR – cumulative drug released.
pH in a sustained manner. Preliminary animal studies revealed that cellulose acetate
phthalate coated tablets markedly reduced the incidence of ulcer in comparison with the
stress control groups, but it requires further studies as a drug delivery system.
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